SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
CYTR Analysis & Videos »
CYTR: Bull or Bear?
Molecular Chaperone Technology
CYTR
|
|
|
+40.06%
in
22 days
CytRx currently has two orally administered, clinical-stage molecular chaperone drug candidates and recently discovered a series of additional compounds that may provide a pipeline for additional drug candidates. The Company's drug candidates are believed to function by regulating a normal cellular protein repair pathway through the activation or inhibition of "molecular chaperones." Because damaged proteins are thought to play a role in many diseases, activation of molecular chaperones that help to reduce the accumulation of misfolded proteins may have therapeutic efficacy in a broad range...
|
Bullish on CYTR ...
CYTR
|
|
|
+0.00%
in
3 minutes
(closed on 10/20/09)
Key Developments: CytRx Corporation Secures European Patent for Arimoclomol September 10, 2009 CytRx Corporation Receives FDA Letter Regarding Arimoclomol Phase IIb Clinical Trial For ALS September 8, 2009 CytRx Corporation's Arimoclomol Demonstrates Statistically Significant Cellular Evidence of Both Neuroprotection and Neuroregeneration in Animal Stroke Study August 24, 2009 CytRx Corporation's Drug Candidate INNO-206 Produces Statistically Significant Tumor Shrinkage in Animal Model of Small Cell Lung Cancer August 12, 2009 CytRx Corporation To Receive FDA Correspondenc...
|
FDA Calendar Updates: POZN, AZN, SNY, CEPH, APPY, CYTR
CYTR
|
|
|
+1.94%
in
149 days
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-st...
|
People Bullish on CYTR
People Bearish on CYTR
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on CYTR |
|
|
|
|
sam1933
(-6.91% risk: conservative)
|
|
|
|
|
|
|
sam1933
(-6.91% risk: conservative)
|
|
CytRx Corporation's oncology pipeline
- CytRx Corporation's oncology pipeline includes three clinical-stage drug candidates in various stages of development, including:
Tamibarotene (...
|
|
|
|
|
sam1933
(-6.91% risk: conservative)
|
|
About ALS
- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, tod...
|
More Resources
|
About CytRx Corp.
- Answers.com
